The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Cardiovascular consequences of metabolic syndrome
Open accessAbstract
The metabolic syndrome (MetS) is defined as the concurrence of obesity-associated cardiovascular risk factors including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, decreased HDL cholesterol, and/or hypertension. Earlier conceptualizations of the MetS focused on insulin resistance as a core feature, and it is clearly coincident with the above list of features. Each component of the MetS is an independent risk factor for cardiovascular disease and the combination of these risk factors elevates rates and severity of cardiovascular disease, related to a spectrum of cardiovascular conditions including microvascular dysfunction, coronary atherosclerosis and calcification, cardiac dysfunction, myocardial infarction, and heart failure. While advances in understanding the etiology and consequences of this complex disorder have been made, the underlying pathophysiologic mechanisms remain incompletely understood, and it is unclear how these concurrent risk factors conspire to produce the variety of obesity-associated adverse cardiovascular diseases. In this review we highlight current knowledge regarding the pathophysiologic consequences of obesity and the MetS on cardiovascular function and disease, including considerations of potential physiologic and molecular mechanisms that may contribute to these adverse outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–215 of 215
Busetto, L., Stefano, F. D., Pigozzo, S., Segato, G., Luca, M. D., & Favretti, F. (2013) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2013.03.010 · Cited by 23
Pioglitazone reverses down-regulation of cardiac PPARγ expression in Zucker diabetic fatty rats
Pelzer, T., Jazbutyte, V., Arias-Loza, P.-A., Segerer, S., Lichtenwald, M., Law, M. P., Schäfers, M. A., Ertl, G., & Neyses, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.029 · Cited by 22
Dyad content is reduced in cardiac myocytes of mice with impaired calmodulin regulation of RyR2
Lavorato, M., Huang, T.-Q., Iyer, V. R., Perni, S., Meissner, G., & Franzini‐Armstrong, C. (2015) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-015-9405-5 · Cited by 21
Impaired cardiac function in leptin-deficient mice
Ren, J. T., & Ma, H. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0084-0 · Cited by 21
Littlejohns, B., Heesom, K. J., Angelini, G. D., & Suleiman, M. S. (2014) · Clinical Proteomics · doi:10.1186/1559-0275-11-34 · Cited by 21
Luiken, J. J. F. P. (2009) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h09-040 · Cited by 19
Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Chugh, S., Suen, C. M., & Gramolini, A. O. (2010) · Current Cardiology Reviews · doi:10.2174/157340310791162631 · Cited by 17
Impact of Obesity and Bariatric Surgery on Metabolism and Coronary Circulatory Function
Valenta, I., Dilsizian, V., Quercioli, A., Juengling, F. D., Ambrosio, G., Wahl, R. L., & Schindler, T. H. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0433-8 · Cited by 15
Teragawa, H., Morita, K., Shishido, H., Otsuka, N., Hirokawa, Y., Chayama, K., Tamaki, N., & Kihara, Y. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1307-6 · Cited by 15
Impact of Obesity in Patients With Congestive Heart Failure
Kunju, S. U., Badarudeen, S., & Schwar, E. R. (2009) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0480 · Cited by 15
Fish Oil Selectively Improves Heart Function in a Mouse Model of Lipid-induced Cardiomyopathy
Khan, R. S., Chokshi, A. D., Drosatos, K., Jiang, H., Yu, S., Harris, C. R., Schulze, P. C., Homma, S., Blaner, W. S., Shulman, G. I., et al. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318283d845 · Cited by 13
Incretin-Related Drug Therapy in Heart Failure
Vest, A. R. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0232-6 · Cited by 10
Central vs. peripheral leptin excess in the pathogenesis of obesity-associated hypertension
Bełtowski, J. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f47688 · Cited by 9
Obesity and Cardiac Metabolism in Women
Taegtmeyer, H., & Algahim, M. F. (2008) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.04.008 · Cited by 4
Is insulin resistance: the link between TG-rich lipoproteins and excess death?
Reaven, G. M. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02460.x · Cited by 4
Cited by
Mechanisms of Oxidative Stress in Metabolic Syndrome
Masenga, S. K., Kabwe, L. S., Chakulya, M., & Kirabo, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097898 · Cited by 717
ACE-inhibition induces a cardioprotective transcriptional response in the metabolic syndrome heart
Yakubova, A., Thorrez, L., Svetlichnyy, D., Zwarts, L., Vulsteke, V., Laenen, G., Oosterlinck, W., Moreau, Y., Dehaspe, L., Van Houdt, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34547-9 · Cited by 397
Body mass index and the risk of infection - from underweight to obesity
Dobner, J., & Kaser, S. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.013 · Cited by 392
Meléndez-Fernández, O. H., Liu, J. A., & Nelson, R. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043392 · Cited by 227
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Metadata
- Authors
- Tune, J. D., Goodwill, A. G., Sassoon, D. J., & Mather, K. J.
- Venue
- Translational Research
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 183
- Pages
- 57-70
- ISSN
- 1878-1810 (ISSN-L)
- 1931-5244
- OpenAlex
- W2570731532
- Cited by
- 568
- References
- 215
- FWCI
- 22.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.